NASDAQ:ALT Altimmune (ALT) Stock Price, News & Analysis $7.55 -0.21 (-2.71%) (As of 12/24/2024 05:19 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Altimmune Stock (NASDAQ:ALT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Altimmune alerts:Sign Up Key Stats Today's Range$7.50▼$7.8050-Day Range$6.69▼$9.8552-Week Range$5.28▼$14.84Volume1.34 million shsAverage Volume3.82 million shsMarket Capitalization$536.99 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingModerate Buy Company OverviewAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Read More… Altimmune Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks41st Percentile Overall ScoreALT MarketRank™: Altimmune scored higher than 41% of companies evaluated by MarketBeat, and ranked 733rd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingAltimmune has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAltimmune has only been the subject of 2 research reports in the past 90 days.Read more about Altimmune's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Altimmune are expected to grow in the coming year, from ($1.36) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Altimmune is -4.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Altimmune is -4.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAltimmune has a P/B Ratio of 2.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted32.94% of the outstanding shares of Altimmune have been sold short.Short Interest Ratio / Days to CoverAltimmune has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Altimmune has recently increased by 2.58%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAltimmune does not currently pay a dividend.Dividend GrowthAltimmune does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted32.94% of the outstanding shares of Altimmune have been sold short.Short Interest Ratio / Days to CoverAltimmune has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Altimmune has recently increased by 2.58%, indicating that investor sentiment is decreasing. News and Social Media2.6 / 5News Sentiment0.68 News SentimentAltimmune has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Altimmune this week, compared to 9 articles on an average week.Search InterestOnly 23 people have searched for ALT on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat FollowsOnly 13 people have added Altimmune to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Altimmune insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Altimmune is held by insiders.Percentage Held by Institutions78.05% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Altimmune's insider trading history. Receive ALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address ALT Stock News HeadlinesWe're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn RateDecember 25 at 10:30 AM | uk.finance.yahoo.comB.Riley Financial Keeps Their Buy Rating on Altimmune (ALT)December 21, 2024 | markets.businessinsider.comYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!December 25, 2024 | WealthPress (Ad)Altimmune, Inc: Altimmune Added to Nasdaq Biotechnology IndexDecember 19, 2024 | finanznachrichten.deAltimmune’s Nasdaq Biotech Index Addition Fuels Retail Enthusiasm, Stock ReboundsDecember 19, 2024 | msn.comWhy Altimmune Was Such a Robustly Healthy Stock on ThursdayDecember 19, 2024 | fool.comAltimmune Added to Nasdaq Biotechnology IndexDecember 19, 2024 | globenewswire.comLightning Round: Ford's warranty problems will come back to haunt it, says Jim CramerDecember 18, 2024 | msn.comSee More Headlines ALT Stock Analysis - Frequently Asked Questions How have ALT shares performed this year? Altimmune's stock was trading at $11.25 at the beginning of 2024. Since then, ALT stock has decreased by 32.9% and is now trading at $7.55. View the best growth stocks for 2024 here. How were Altimmune's earnings last quarter? Altimmune, Inc. (NASDAQ:ALT) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03. The company earned $0.01 million during the quarter. Altimmune had a negative trailing twelve-month return on equity of 55.81% and a negative net margin of 199,076.92%. When did Altimmune's stock split? Altimmune shares reverse split on the morning of Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Altimmune's major shareholders? Top institutional shareholders of Altimmune include State Street Corp (4.80%), Geode Capital Management LLC (2.35%), Bellevue Group AG (1.22%) and GSA Capital Partners LLP (0.48%). Insiders that own company stock include Vipin K Garg, David Drutz, Matthew Scott Harris, Wayne Pisano, M Scot Roberts and Diane Jorkasky. View institutional ownership trends. How do I buy shares of Altimmune? Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Altimmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that Altimmune investors own include Invesco QQQ (QQQ), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE) and SPDR S&P 500 ETF Trust (SPY). Company Calendar Last Earnings11/12/2024Today12/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALT CUSIPN/A CIK1326190 Webaltimmune.com Phone(240) 654-1450Fax410-269-2601Employees50Year FoundedN/APrice Target and Rating Average Stock Price Target$20.00 High Stock Price Target$26.00 Low Stock Price Target$12.00 Potential Upside/Downside+164.9%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,450,000.00 Net Margins-199,076.92% Pretax Margin-199,076.92% Return on Equity-55.81% Return on Assets-50.60% Debt Debt-to-Equity RatioN/A Current Ratio16.87 Quick Ratio16.87 Sales & Book Value Annual Sales$52,000.00 Price / Sales10,326.80 Cash FlowN/A Price / Cash FlowN/A Book Value$2.75 per share Price / Book2.75Miscellaneous Outstanding Shares71,125,000Free Float68,209,000Market Cap$536.99 million OptionableOptionable Beta0.15 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ALT) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.